PROTAC RIPK1 Degrader-1
PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S, R, S) -AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373).
Product Specifications
UNSPSC
12352005
Target
PROTACs; RIP kinase
Related Pathways
Apoptosis; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(N1CCC(CC1)CN2CCC(CN3CCN(CC(N[C@H](C(N4[C@H](C(N[C@@H](C)C5=CC=C(C6=C(C)N=CS6)C=C5)=O)C[C@@H](O)C4)=O)C(C)(C)C)=O)CC3)CC2)CN7C=C(C=N7)C8=CN=C(N)C9=C8SC=C9C%10=CC=C%11N(C(CC%12=CC=CC=C%12)=O)CCC%11=C%10
Molecular Formula
C69H85N13O6S2
Molecular Weight
1256.63
References & Citations
[1]Zhang Z, et al. Development of Potent and Selective RIPK1 Degraders Targeting Its Nonenzymatic Function for Cancer Treatment. J Med Chem. 2025 Jul 24;68 (14) :15120-15136.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1; von Hippel-Lindau (VHL)
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0864407 1.0 µg DNA
GLC1M sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
Sign In for Pricing
View Details 
NBP2-11762-0.025mg 0.025 mg
Mouse Monoclonal KIR2DS4/CD158i Antibody (MM0442-2G42)
Sign In for Pricing
View Details VK617040-01 50 µg
InVivoMAb Anti-HIV-1 gp140/Env Trimer Broadly Neutralizing Antibody (Iv0112)
Sign In for Pricing
View Details VK617040-02 100 µg
InVivoMAb Anti-HIV-1 gp140/Env Trimer Broadly Neutralizing Antibody (Iv0112)
Sign In for Pricing
View Details